Live feed07:00:00·258dPRReleasevia QuantisnowMBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label ExtensionByQuantisnow·Wall Street's wire, on your screen.MBX· MBX Biosciences Inc.Health Care
